Related Experiment Videos
CD34 expression by gastrointestinal tract stromal tumors
M van de Rijn1, M R Hendrickson, R V Rouse
1Department of Pathology, Stanford University School of Medicine, CA 94305.
Human Pathology
|August 1, 1994
Summary
CD34 monoclonal antibody My10 is a useful diagnostic marker for gastrointestinal stromal tumors (GISTs). This antibody reacts with 83% of GISTs, aiding in the diagnosis of challenging cases, particularly those with epithelioid morphology.
Area of Science:
- Oncology
- Pathology
- Immunohistochemistry
Background:
- Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms of the GI tract.
- GISTs often exhibit smooth muscle differentiation but can lack typical markers.
- Epithelioid GISTs can be misdiagnosed as carcinomas or melanomas.
Purpose of the Study:
- To evaluate the utility of the CD34 monoclonal antibody My10 in diagnosing GISTs.
- To assess CD34 reactivity in GISTs, including those with epithelioid morphology.
- To differentiate GISTs from other neoplasms based on CD34 expression.
Main Methods:
- Immunohistochemical staining using the CD34 monoclonal antibody My10.
- Assessment of reactivity in 23 GIST cases with varying morphology.
- Immunoblotting to determine the molecular weight of the CD34 antigen.
Main Results:
- CD34 antibody My10 reacted with 19 of 23 (83%) GISTs.
- Six GISTs lacking muscle-specific markers (MSA, SMA, desmin) were CD34 reactive.
- CD34 reactivity in GISTs is more frequent and intense than in other smooth muscle neoplasms.
Conclusions:
- CD34 is a valuable marker for diagnosing GISTs, especially epithelioid variants.
- CD34 expression aids in differentiating GISTs from other tumors.
- CD34 reactivity in GISTs is distinct from smooth muscle neoplasms.